Table of Contents
- Product Overview & Specifications
- Key Applications & Uses
- Industry Case Studies
- Usage Guidelines
- Client Success Stories
- Contact for Technical Support
Product Overview & Specifications
Lappaconitine Hydrobromide (CAS 97792-45-5)
| Parameter | Specification | Competitor A | Competitor B |
|---|---|---|---|
| Purity | ≥99.5% | 98.0-99.0% | 97.5-98.5% |
| Solubility | Water-soluble | Organic solvents | Partial solubility |
| Storage | 2-8°C sealed | Room temperature | Refrigerated |
Key Applications & Uses
Pharmaceutical Applications
Primarily used as:
- Non-opioid analgesic for neuropathic pain management
- Anti-arrhythmic agent in cardiovascular research
- Lead compound in novel anti-inflammatory drug development
Research Applications
- Ion channel modulation studies
- Neurological disorder research models
- Comparative alkaloid analysis
Industry Case Studies
Pain Management Formulation
European pharma company achieved 40% reduction in opioid dependence using lappaconitine-based therapy in Phase II trials.
Cardiovascular Research
University research team successfully stabilized ventricular tachycardia in animal models using 0.15mg/kg dosage.
Usage Guidelines
| Application | Recommended Concentration | Solvent Compatibility |
|---|---|---|
| In vitro studies | 10-50 μM | PBS, DMSO (<0.1%) |
| Animal models | 0.1-0.3 mg/kg | Saline solution |
Client Success Stories
Case 1: Neuropathic Pain Treatment
Client: Asia-based Biotech Ltd.
Application: Developed sustained-release tablets showing 72% pain reduction in post-herpetic neuralgia patients.
Case 2: Arrhythmia Research
Client: North American Research Institute
Result: Achieved 89% success rate in suppressing atrial fibrillation episodes in preclinical models.
Contact for Technical Support
Email: info@vivalr.com
Phone: (86) 15866781826
Request batch-specific COA or formulation consultation:
- Custom purity requirements (95%-99.9%)
- Bulk ordering (100g-50kg batches)
- GMP-grade manufacturing



评论
目前还没有评论。